U.S. lawmakers ramp up scrutiny of FDA following agency’s approval of controversial Alzheimer’s drug
By
Alicia Lasek
Sep 07, 2021
The FDA is being asked to help explain how Aduhelm (aducanumab) met accelerated approval criteria when so many experts — including internal advisers — have flagged insufficient safety and efficacy...
The calculation method for Medicare readmissions penalties should be risk-adjusted so that providers do not lose money for serving the sickest, poorest seniors, a bipartisan group of Congressional lawmakers...